Johnson & Johnson Receives FDA Approval For Its Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Platform

The Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single catheter.i "The FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform is another important milestone in what has been an incredible pace of innovation for our business," said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson. "Our goal has always been to put the best possible technologies into physicians’ hands so they can treat increasingly complex cases with confidence.

Following a successful introduction in Europe, we’re pleased to rapidly expand access to this technology in the U.S. and continue building on the momentum of one of the most active innovation periods in our history." Built on the THERMOCOOL SMARTTOUCH SF Platform, which has extensive clinical validation and has treated over one million patients in the U.S., the DE STSF Platform brings pulse field capability to a catheter physicians know and trust.i The DE STSF platform is integrated with the CARTO ecosystem, including advanced mapping, imaging and PF Index guidance, helping physicians confidently deliver energy with precise contact force while supporting a predictable procedure and reproducible workflow.

The dual energy capability gives physicians the versatility to use RF or PF energy based on patient anatomy and case complexity.i